Thursday, July 13, 2017 6:15:25 PM
Question
Now moving to clinical questions. What are management's thoughts on Brilacidin and inflammatory bowel disease? The interim data you released seems very promising.
Leo Ehrlich
Yes indeed. We're extremely excited about what we've been seeing with Brilacidin in IBD. It's really a novel non-corticosteroid non-biologic treatment that I think will have a very good place in treatment of various disorders.
We posted a strong interim data through two cohorts 12 patients. Our clinical position as I mentioned earlier was seen in at least half of the patients treated, I got a well-tolerated safety profile and from our measurements of systemic absorption they're really negligible, they are very low.
Patient improvement in quality of life was also seen across the study. So, we used [indiscernible]. Not everybody does that. We did this as a component to clinical remission criteria to really set the bar and that supports objectives corroboration of the patient responses. So that really helps us to anchor the results that we've seen.
We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking.
A recent example of an IBD deal just last week Johnson & Johnson signed a $990 million deal with Protagonist Therapeutics for preclinical compound with the bulk of the payout tied to advancing the compound into Phase 2 trials, that's where we are at this point. So, I essentially feel really good about where we are with Brilacidin in IBD.
Approximately a third of IBD patients find that existing treatments are not affective, that's why there's a high demand for a new treatment and a huge commercial opportunity.
As mentioned earlier we will be presenting topline findings from a clinical trial ulcerative proctitis, ulcerative proctosigmoiditis across all three cohorts in July in Boston at the DDT World Congress, as well as meeting with third parties interested in taking a closer look at our data.
Question
It's a question for Dr. Bertolino. I appreciate your mention of Brilacidin as a franchise. I think that's a nice word choice. I am especially also interested in your attempts to get the rest of the colon and the small intestine.
Can you provide any information about attempts to develop an enteric formulation for Brilacidin?
Arthur Bertolino
Yes, absolutely you're right on target with that and I think as I mentioned earlier, half of inflammatory bowel disease or more is Crohn's disease and Crohn's disease can happen anywhere in the GI tract. It's not just at the distal end like in the ulcerative colitis where we're getting the exciting results.
So, I think based on the results that we've gotten so far that we can get the drug into the GI tract without getting very much in the way of systemic absorption, it's an obvious direction that we would want to go to try to formulate a pill delivery.
So, it could treat throughout the GI tract and the technology for those kinds of deliveries have really gotten quite impressive in recent years that you can actually target certain areas of the GI tract where you can get pills to provide the active pharmaceutical ingredient to come out of the pill housing.
So, I think it would not be reinventing the wheel on how to do that. A lot of big pharms right now understand that themselves. Some actually have the technology available, but maybe lacking in terms of the right drug candidate with enough horsepower to treat the disease.
So that really just sets us up as Leo mentioned again toward a partnership. If that's appreciated, I think we could be in very good shape to move that in that direction without having to reinvent the wheel and really coming across the finish line effectively.
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript?part=single
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM